Laboratory of Physical Pharmaceutics

2017

  1. T. Higashi, D. Iohara, K. Motoyama, H. Arima,
    Supramolecular Pharmaceutical Sciences: A Novel Concept Combining Pharmaceutical Sciences and Supramolecular Chemistry with Focus on Cyclodextrin-based Supermolecules,
    Chem. Pharm. Bull., in press (2017).
  2. R. Tabuchia, M. Anraku, D. Iohara, T. Ishiguro, S. Ifuku, T. Nagae, K. Uekama, S. Okazak, K. Takeshita, M. Otagiri, F. Hirayama,
    Surface-deacetylated chitin nanofibers reinforced with a sulfobutyl ether β-cyclodextrin gel loaded with prednisolone as potential therapy for inflammatory bowel disease,
    Carbohyd. Polym., 174, 1087-1094 (2017).
  3. D. Iohara, M. Okubo, M. Anraku, S. Uramatsu, T. Shimamoto, K. Uekama and F. Hirayama,
    Hydrophobically Modified Polymer/α-Cyclodextrin Thermoresponsive Hydrogels for Use in Ocular Drug Delivery,
    Mol. Pharmaceutics, 14, 2740-2748 (2017).
  4. M. Anrakua, R. Tabuchi, S. Ifuku, T. Nagae, D. Iohara, H. Tomida, K. Uekama, T. Maruyama, S. Miyamura, F. Hirayama, M. Otagiri,
    An oral absorbent, surface-deacetylated chitin nano-fiber ameliorates renal injury and oxidative stress in 5/6 nephrectomized rats,
    Carbohyd. Polym., 161, 21-25 (2017).
  5. K. Shimoishi, M. Anrakua, A. Uto, D. Iohara, F. Hirayama, D. Kadowaki, S. Zingami, T. Maruyama and M. Otagiri,
    A Comparison of the Phosphorus Content in Prescription Medications for Hemodialysis Patients in Japan,
    YAKUGAKU ZASSHI, 137, 903-908 (2017).

2016

  1. R. Tabuchi, K. Azuma, R. Izumi, T. Tanou, Y. Okamoto, T. Nagae, D. Iohara, K. Uekama, M. Otagiri, F. Hirayama, S. Ifuku, M. Anraku,
    Biomaterials based on freeze dried surface-deacetylated chitin nanofibers reinforced with sulfobutyl ether β-cyclodextrin gel in wound dressing applications,
    Int. J. Pharm., 511, 1080-1087 (2016).
  2. Y. Inoue, D. Iohara, N. Sekiya, M. Yamamoto, H. Ishida, Y. Sakiyama, F. Hirayama, H. Arima, K. Uekama,
    Ternary Inclusion Complex Formation and Stabilization of Limaprost, A Prostaglandin E1 Derivative, in the Presence of α- and β-cyclodextrins in the solid state,
    Int. J. Pharm., 509, 338-347 (2016).
  3. D. Iohara, Y. Umezaki, M. Anraku, K. Uekama and F. Hirayama,
    In vitro and In vivo Evaluation of Hydrophilic C60OH10/2-Hydroxypropyl-β-cyclodextrin Nanoparticles as an Antioxidant,
    J. Pharm. Sci., 105, 2959-2965 (2016).
  4. Y. Kouno, M. Anraku, K. Yamasaki, Y. Okayama, D. Iohara, H. Nakamura, T. Maruyama, F. Hirayama, U. K. Hansene, M. Otagiri,
    N-acetyl-L-methionine is a superior protectant of human serum albumin against post-translational oxidation as compared to N-acetyl-L-tryptophan,
    Biochem. Biophys. Rep., 6, 266-274 (2016).
  5. K. Igami, M. Ozawa, S. Inoue, D. Iohara, T. Miyazaki, M. Shinoda, M. Anraku, F. Hirayama and K. Uekama
    The formation of an inclusion complex between a metabolite of ginsenoside, compound K, and γ-cyclodextrin and its dissolution characteristics,
    J. Pharm. Pharmacol, 68, 608-614 (2016).
  6. M. Anraku, D. Iohara, K. Wadad, K. Taguchi, T. Maruyama, M. Otagiri, K. Uekama, F. Hirayama,
    Antioxidant and renoprotective activity of 2-hydroxypropyl-β-cyclodextrin in nephrectomized rats,
    J. Pharm. Pharmacol, 68, 646-654 (2016).
  7. T. Higashi, J. Li, X. Song, J. Zhu, M. Taniyoshi, F. Hirayama, D. Iohara, K. Motoyama and H. Arima,
    Thermoresponsive Formation of Dimethyl Cyclodextrin Polypseudorotaxanes and Subsequent One-Pot Synthesis of Polyrotaxanes,
    ACS Macro Lett., 5, 158-162 (2016).

2015

  1. M. Anraku, R. Tabuchi, S. Ifuku, T. Ishiguro, D. Iohara and F. Hirayama
    Surface-Deacetylated Chitin Nano-Fiber/Hyaluronic Acid Composites as Potential Antioxidative Compounds for Use in Extended-Release Matrix Tablets,
    Int. J. Mol. Sci., 16, 24707-24717 (2015).
  2. M, Anraku, A. Hiraga, D. Iohara, J. D. Pipkin, K. Uekama, F. Hirayama,
    Slow-release of famotidine from tablets consisting of chitosan/sulfobutyl ether β-cyclodextrin composites,
    Int. J. Pharm., 487, 142-147 (2015).
  3. Y. Inoue, N. Sekiya, M. Yamamoto, D. Iohara, F. Hirayama, K. Uekama,
    Formation of Ternary Inclusion Complex of Limaprost with α- and β-Cyclodextrins in Aqueous Solution,
    Chem. Phram. Bull., 63, 318-325 (2015).
  4. Y. Umezaki, D. Iohara, M. Anraku, Y. Ishitsuka, T. Irie, K. Uekama and F. Hirayama,
    Preparation of Hydrophilic C60(OH)10/2-Hydroxypropyl-β-cyclodextrin Nanoparticles for the Treatment of a Liver Injury Induced by an Overdose of Acetaminophen,
    Biomaterials, 45, 115-123 (2015).
  5. M. Anraku, D. Iohara, A. Hiraga, K. Uekama, S. Ifuku, J. D. Pipkin and F. Hirayama,
    Formation of Elastic Gels from Surface-deacetylated Chitin Nanofibers Reinforced with Sulfobutyl Ether β-Cyclodextrin,
    Chem. Lett., 44, 285-287(2015).

2014

  1. M. Anraku, M. Tanaka, A. Hiraga, K. Nagumo, T. Imafuku, Y. Maezaki, D. Iohara, K. Uekama, H. Watanabe, F. Hirayama, T. Maruyama, M. Otagiri,
    Effects of chitosan on oxidative stress and related factors in hemodialysis patients,
    Carbohyd. Polym., 112, 152-157 (2014).
  2. Y. Kouno, M. Anraku, K. Yamasaki, Y. Okayama, D. Iohara, Y. Ishima, T. Maruyama, U. Kragh-Hansene, F. Hirayama, M. Otagiri,
    N-acetyl-L-methionine is a superior protectant of human serum albumin against photo-oxidation and reactive oxygen species compared to N-acetyl-L-tryptophan ,
    BBA-General Subjects, 1840, 2806-2812 (2014).
  3. Y. Inoue, N. Sekiya, K. Katayama, S. Narutaki, M. Yamamoto, D. Iohara, F. Hirayama, K. Uekama,
    Stabilizing Effect of β-Cyclodextrin on Limaprost, a PGE1 Derivative, in Limaprost Alfadex Tablets (Opalmon®) in Highly Humid Conditions,
    Chem. Pharm. Bull., 62, 786-792 (2014).
  4. M. Anraku, A. Hiraga, D. Iohara, K. Uekama, H. Tomida, M. Otagiri, F. Hirayama,
    Preparation and antioxidant activity of PEGylated chitosans with different particle sizes,
    Int. J. Biol. Macromol., 70, 64-69 (2014).
  5. H. Aldawsari, A. Altaf, Z. M. Banjar, M. Okubo, D. Iohara, M. Anraku, F. Hirayama and K. Uekama,
    Combined Use of Cyclodextrins and Hydroxypropylmethylcellulose Stearoxy Ether (Sangelose®) for the Preparation of Orally Disintegrating Tablets of Type-2 Antidiabetes Agent Glimepiride,
    J. Inclusion Phenom. Macrocyclic Chem., 80, 61-67 (2014).
  6. A. Altaf, H. Aldawsari, Z. M. Banjar, D. Iohara, M. Anraku, K. Uekama, F. Hirayama,
    Potential Use of C60/2-Hydroxypropyl-β-cyclodextrin Nanoparticles as a New Photosensitizer in the Treatment of Cancer,
    Int. J. Photoenergy., Article ID 570506 (2014).
  7. 安楽 誠
    血清アルブミンの酸化ストレス解明と酸化ストレス関連疾患への展開,
    薬学雑誌, 134,(9), 973-979 (2014).

2013

  1. A. Altaf, H. Aldawsari, Z. M. Banjar, M. Anraku, D. Iohara, M. Otagiri, K. Uekama, F. Hirayama,
    Preparation of soluble stable C60/human serum albumin nanoparticles via cyclodextrin complexation and their reactive oxygen production characteristics,
    Life Sci., 93, 277-282 (2013).
  2. H. Aldawsari, A. Altaf, Z. M. Banjar, D. Iohara, M. Nakabayashi, M. Anraku, K. Uekama and F. Hirayama,
    Crystallization of A New Polymorph of Acetohexamide from 2-Hydroxybutyl-β-cyclodextrin Solution: Form VI with A High Aqueous Solubility,
    Int. J. Pharm., 453, 315-321 (2013).
  3. 上釜兼人、平山文俊、安楽誠、庵原大輔
    各種薬物の製剤特性改善におけるシクロデキストリンの有用性, "シクロデキストリンの科学と技術", 寺尾 啓二,池田 宰(監修), シーエムシー出版, 東京, 2013, pp. 124-133.

2012

  1. D. Iohara, K. Yoshida, K. Yamaguchi, M. Anraku, K. Motoyama, H. Arima, K. Uekama and F. Hirayama,
    Cyclodextrin-induced Change in Crystal Habit of Acetylsalicylic Acid in Aqueous Solution,
    Cryst. Growth Des., 12(4), 1985-1991 (2012).
  2. M. Anraku, H. Tomida, A. Michihara, D. Tsuchiya, D. Iohara, Y. Maezaki, K. Uekama, T. Maruyama, M. Otagiri and F. Hirayama,
    Antioxidant and Renoprotective Activity of Chitosan in Nephrectomized Rats,
    Carbohydr. Polym., 89, 302-304 (2012).
  3. H. Arima, M. Arizono, T. Higashi, A. Yoshimatsu, H. Ikeda, K. Motoyama, K. Hattori, T. Takeuchi, F. Hirayama and K. Uekama,
    Potential Use of Folate-polyethylene glycol (PEG)-Appended Dendrimer (G3) Conjugate with a-Cyclodextrin as DNA Carriers to Tumor Cells,
    Cancer Gene Ther., 19(5), 358-366 (2012).
  4. T. Anno, T. Higashi, K. Motoyama, F. Hirayama, K. Uekama and H. Arima,
    Possible Enhancing Mechanisms for Gene Transfer Activity of Glucuronylglucosyl-β-cyclodextrin/dendrimer Conjugate (G2),
    Int. J. Pharm., 426(1-2), 239-247 (2012).
  5. D. Iohara, M. Hiratsuka, F. Hirayama, K. Takeshita, K. Motoyama, H. Arima and K. Uekama,
    Evaluation of photodynamic activity of C60/2-hydroxypropyl-β-cyclodextrin nanoparticles,
    J. Pharm. Sci.,101(9), 3390-3397 (2012).
  6. T. Anno, T. Higashi, K. Motoyama, F. Hirayama, K. Uekama and H. Arima ,
    Potential use of glucuronylglucosyl-β-cyclodextrin/dendrimer conjugate (G2) as a DNA carrier in vitro and in vivo,
    J. Drug Target., 20(3), 272-280 (2012).
  7. K. Uehata, T. Anno, K. Hayashida, T. Higashi, K. Motoyama, F. Hirayama, K. Uekama and H. Arima,
    Peak-less Hypoglycemic Effect of Insulin Glargine by Complexation with Maltosyl-β-cyclodextrin,
    Int. J. Pharm., 422(1-2), 33-39 (2012).
  8. 上釜兼人
    シクロデキストリンを基盤にした新規製剤設計へのアプローチ,
    薬学雑誌, 132,(1), 85-105 (2012).
  9. 有馬英俊、本山敬一、東 大志、上釜兼人
    シクロデキストリンを用いた難水溶性薬物の溶解性ならびに吸収性の改善, "難吸収性薬物の吸収性改善と新規投与製剤の開発", 山本 昌(監修), シーエムシー出版, 東京, 2012, pp. 8-17.
  10. 本山敬一、東 大志、平山文俊、上釜兼人、有馬英俊
    シクロデキストリンポリシュードロタキサンを用いたタンパク質・遺伝子徐放システム,
    PHARM TECH JAPAN,28(10), 169-177 (2012).

2011

  1. K. Uehata, T. Anno, K. Hayashida, K. Motoyama, T. Higashi, F. Hirayama, N. Ono , J.D. Pipkin, K. Uekama and H. Arima,
    Effects of Selected Anionic β-Cyclodextrins on Persistence of Blood Glucose Lowering by Insulin Glargine after Subcutaneous Injection to Rats,
    J. Drug Delivery, 2011, 1-9 (2011).
  2. H. Arima, T. Tsutsumi, A. Yoshimatsu, H. Ikeda, K. Motoyama, T. Higashi, F. Hirayama and K. Uekama,
    Inhibitory Effect of siRNA Complexes with Polyamidoamine Dendrimer/a-Cyclodextrin Conjugate (Generation 3, G3) on Endogenous Gene Expression,
    Eur. J. Pharm. Sci., 44(3), 375-384 (2011).
  3. T. Ishiguro, E. Morishita, D. Iohara, F. Hirayama, K. Wada, K. Motoyama, H. Arima and K. Uekama,
    Some pharmaceutical and inclusion properties of 2-hydroxybutyl-β-cyclodextrin derivative,
    Int. J. Pharm., 419(1-2), 161-169 (2011).
  4. K. Uehata, T. Anno, K. Hayashida, K. Motoyama, F. Hirayama, N. Ono, J.D. Pipkin, K. Uekama and H. Arima,
    Effect of Sulfobutyl ether-β-cyclodextrin on Bioavailability of Insulin Glargine and Blood Glucose Level after Subcutaneous Injection to Rats,
    Int. J. Pharm., 419(1-2), 71-76 (2011).
  5. Y. Miyamoto, M. Nakahara, K. Motoyama, T. Ishiguro, Y. Oda, T. Yamanoi, I. Okamoto, A. Yagi, H. Nishimura, F. Hirayama, K. Uekama and H. Arima,
    Improvement of Some Physicochemical Properties of Arundic Acid, (R)-(-)-2-Propyloctanonic Acid, by Complexation with Hydrophilic Cyclodextrins,
    Int. J. Pharm., 413(1-2), 63-72 (2011).
  6. D. Iohara, F. Hirayama, K. Higashi, K. Yamamoto and K. Uekama,
    Formation of Stable Hydrophilic C60 Nanoparticles by 2-Hydroxypropyl-β-cyclodextrin,
    Mol. Pharmaceutics, 8, 1276-1284(2011).
  7. N. Ono (nee Yoshida), Y. Miyamoto, T. Ishiguro, K. Motoyama, F. Hirayama, D. Iohara, H. Seo, S. Tsuruta, H. Arima, K. Uekama,
    Reduction of Bitterness of Antihistaminic Drugs by Complexation with β-Cyclodextrins,
    J. Pharm. Sci., 100(5), 1935-1943(2011).
  8. T. Anno, K. Motoyama, T. Higashi, F. Hirayama, K. Uekama, H. Arima,
    Preparation and Evaluation of Polyamidoamine Dendrimer (G2)/Branched-β-cyclodextrin Conjugate as a Novel Gene Transfer Carrier,
    J. Incl. Phenom. Macrocycl. Chem., 70, 339-344 (2011).
  9. K. Motoyama, Y. Mori, S. Yamashita, Y. Hayashi, H. Jono, Y. Ando, F. Hirayama, K. Uekama, H. Arima,
    In Vitro Gene Delivery Mediated by Lactosylated Dendrimer (generation 3, G3)/α-Cyclodextrin Conjugates into Hepatocytes,
    J. Incl. Phenom. Macrocycl. Chem., 70, 333-338 (2011).
  10. K. Motoyama, Y. Nakashima, Y. Aramaki, F. Hirayama, K. Uekama, H. Arima,
    In Vitro Gene Delivery Mediated by Asialofetuin-appended Cationic Liposomes Associated with γ-Cyclodextrin into Hepatocytes,
    J. Drug Delivery, 2011, 1-33 (2011).

2010

  1. H. Arima, S. Yamashita, Y. Mori, Y. Hayashi, K. Motoyama, K. Hattori, T. Takeuchi, H. Jono, Y. Ando, F. Hirayama, K. Uekama,
    In Vitro and In Vivo Gene Delivery Mediated by Lactosylated Dendrimer/α-Cyclodextrin Conjugates (G2) into Hepatocytes,
    J. Control. Release, 146(1), 106-117 (2010).
  2. F. Mady, A. Abou-Taleb, K. Khaled, K. Yamasaki, D. Iohara, T. Ishiguro, F. Hirayama, K, Uekama and M. Otagiri,
    Enhancement of the Aqueous Solubility and Masking the Bitter Taste of Famotidine Using Drug/SBE-β-CyD/Povidone K30 Complexation Approach,
    J. Pharm. Sci., 99, 4285-4294 (2010).
  3. F. Mady, A. Abou-Taleb, K. Khaled, K. Yamasaki, D. Iohara, K. Taguchi, M. Anraku, F. Hirayama, K, Uekama and M. Otagiri,
    Evaluation of carboxymethyl-β-cyclodextrin with acid function: Improvement of chemical stability, oral bioavailability and bitter taste of famotidine,
    Int. J. Pharm., 397(1), 1-8 (2010).
  4. T. Ishiguro, F. Hirayama, D. Iohara, H. Arima, K. Uekama,
    Crystallization and Polymorphic Transition of Chlorpropamide in Aqueous 2-Hydroxybutyl-β-cyclodextrin Solution,
    Eur. J. Pharm. Sci., 39(4), 248-255 (2010).
  5. K. Udo, K. Hokonohara, K. Motoyama, H. Arima, F. Hirayama, K. Uekama,
    5-Fluorouracil acetic acid/b-cyclodextrin conjugates: Drug release behavior in enzymatic and rat cecal media,
    Int. J. Pharm., 388(4), 95-100 (2010).

2009

  1. K. Motoyama, K. Nagatomo, O.A.E. Soliman, F. Hirayama, K. Uekama, H. Arima,
    Potential Use of 2-Hydroxypropyl-β-cyclodextrin for Preparation of Orally Disintegrating Tablets Containing dl-α-Tocopherol Acetate, an Oily Drug,
    Chem. Pharm. Bull., 57, 1206-1212 (2009).
  2. D. Iohara, F. Hirayama, H. Kansui, H. Aoshima, S. Yamana, M. Yano, J. Kitaguchi, S. Takashima, K. Uekama,
    Preparation of Hydrophilic Nanoparticles of C60 with High Resistance to Aggregation during Storage, Using 2-Hydroxypropyl-β-cyclodextrin,
    Chem. Lett., 38, 1104-1105 (2009).
  3. K. Motoyama, K. Kameyama, R. Onodera, N. Araki, F. Hirayama, K. Uekama, H. Arima,
    Involvement of PI3K-Akt-Bad pathway in apoptosis induced by 2,6-di-O-methyl-β-cyclodextrin, not 2,6-di-O-methyl-β-cyclodextrin, through cholesterol depletion from lipid rafts on plasma membranes in cells,
    Eur. J. Pharm. Sci., 38, 249-261 (2009).
  4. T. Higashi, K. Nishimura, A. Yoshimatsu, H. Ikeda, K. Arima, K. Motoyama, F. Hirayama, K. Uekama and H. Arima,
    Preparation of Four Types of Coenzyme Q10/γ-Cyclodextrin Supramolecular Complexes and Comparison of Their Pharmaceutical Properties,
    Chem. Pharm. Bull., 57(9), 965-970 (2009).
  5. T. Higashi, F. Hirayama, S. Yamashita, S. Misumi, H. Arima and K. Uekama,
    Slow-release System of Pegylated Lysozyme Utilizing Formation of Polypseudorotaxanes with Cyclodextrins,
    Int. J. Pharm., 374 (5), 26-32 (2009).
  6. T. Higashi, F. Hirayama, S. Misumi, K. Motoyama, H. Arima and K. Uekama,
    Polypseudorotaxane Formation of Randomly-Pegylated Insulin with Cyclodextrins: Slow Release and Resistance to Enzymatic Degradation,
    Chem. Pharm. Bull., 57 (5), 541-544 (2009).
  7. K. Motoyama, H. Toyodome, R. Onodera, T. Irie, F. Hirayama, K. Uekama, H. Arima,
    Involvement of Lipid Rafts of Rabbit Red Blood Cells in Morphological Changes Induced by Methylated β-Cyclodextrins,
    Biol. Pharm. Bull., 32 (5), 700-705 (2009).
  8. K. Motoyama, Y. Hashimoto, F. Hirayama, K. Uekama, H. Arima,
    Inhibitory Effects of 2,6-Di-O-methyl-β-cyclodextrin on Poly I:C Signaling in Macrophages,
    Eur. J. Pharm. Sci., 35, 285-291 (2009).
  9. 上釜兼人,平山文俊,庵原大輔,
    シクロデキストリンを用いた製剤からの薬物溶出性, 吸収性の改善,
    ファルマシア, 45, 1223-1227 (2009).

2008

  1. T. Higashi, F. Hirayama, S. Misumi, H. Arima and K. Uekama,
    Design and Evaluation of Polypseudorotaxanes of Pegylated Insulin with Cyclodextrins as Sustained Release System,
    Biomaterials, 29 (8), 3866-3871 (2008).
  2. T. Ishiguro, F. Hirayama, D. Iohara and K. Uekama,
    Prominent inhibitory Effect of 2-Hydroxybutyl-β-cyclodextrin on Solution-mediated Polymorphic Transition of Chlorpropamide,
    Chem. Lett., 37 (8), 816-817 (2008).
  3. K. Nishimura, T. Higashi, A. Yoshimatsu, F. Hirayama, K. Uekama and H. Arima,
    Pseudorotaxane-like Supramolecular Complex of Coenzyme Q10 with γ-cyclodextrin Formed by Solubility Method,
    Chem. Pharm. Bull., 56 (5), 701-706 (2008).
  4. N. Sekiya, A. Nishiwaki, A. Nishiura, M. Yamamoto, K. Takeda, D. Iohara, F. Hirayama, H. Arima and K. Uekama,
    Improved Stability of OPALMON® Tablets under Humid Conditions IV: Formulation Development Study,
    Chem. Pharm. Bull., 56 (1), 7-11 (2008).
  5. D. Iohara, F. Hirayama, T. Ishiguro, H. Arima and K. Uekama,
    Preparation of Amorphous Indomethacin from Aqueous 2,6-Di-O-methyl-β-cyclodextrin Solution,
    Int. J. Pharm., 354 (1-2), 70-76 (2008).
  6. T. Tsutsumi, F. Hirayama, K. Uekama and H. Arima,
    Potential use of Polyamidoamine Dendrimer/α-Cyclodextrin Conjugate (generation 3, G3) as a Novel Carrier for Short Hairpin RNA-Expressing Plasmid DNA,
    J. Pharm. Sci., 97 (8), 3022-3034 (2008).
  7. K. Uekama and F. Hirayama,
    Improvement of Drug Properties by Cyclodextrins, "The Practice of Medicinal Chemistry (3rd version)", Ed. by C. G. Wermuth, Academic Press Limited, London, 2008, pp. 813-840.
  8. 上釜兼人
    Drug Delivery System, "シクロデキストリンの応用技術", 寺尾啓二,小宮山真(監修), シーエムシー出版, 東京, 2008, pp. 159-170.

2007

  1. T. Higashi, F. Hirayama, H. Arima, K. Uekama,
    Polypseudorotaxanes of Pegylated Insulin with Cyclodextrins: Application to Sustained Release System,
    Bioorg. Med. Chem. Lett., 17 (7) 1871-1874 (2007).
  2. K. Anzai, J. Mizoguchi,T. Yanagi, F. Hirayama, H. Arima, K. Uekama,
    Improvement of Dissolution Properties of a New Helicobacter pylori Eradicating Agent (TG44) by Inclusion Complexation with β-Cyclodextrin,
    Chem. Pharm. Bull., 55 (10) 1466-1470 (2007).
  3. T. Tsutsumi, F. Hirayama, K. Uekama, H. Arima,
    Evaluation of Polyamidoamine Dendrimer/α-cyclodextrin Conjugate (Generation 3, G3) as a Novel Carrier for Small Interfering RNA (siRNA),
    J. Controlled Release, 119 (3) 349-359 (2007).
  4. F. Hirayama, K. Uekama,
    Colonic Delivery, "Prodrugs: Challenges and Rewards", Vol. 4 in AAPS Series, "Biotechnology: Pharmaceutical Aspects", AAPS Press, 2007, pp. 683-699.
  5. H. Arima, K. Uekama,
    Cyclodextrins and Other Enhancers in Rectal Delivery, "Enhancement in Drug Delivery", CRC Press, Boca Raton, Florida, 2007, pp. 147-172.
  6. 平山文俊,園田 陽,庵原大輔,有馬英俊,上釜兼人,
    ジメチル-β-シクロデキストリン包接を利用した準安定形結晶の選択的調製, ファ-ム・テク・ジャパン,23, 155-161 (2007).
  7. 上釜兼人, 平山文俊, 有馬英俊,
    シクロデキストリンの製剤への新たな利用展開, 薬剤学, 67 (2), 66-79 (2007).
  8. 有馬英俊,上釜兼人,
    トランスポーターの機能および膜局在性におよぼすメチル化シクロデキストリンの影響バイオインダストリー, 24 (3), 35-43 (2007).
  9. 有馬英俊, 石黒貴子, 平山文俊, 上釜兼人, 入江徹美,
    "食品・医薬品の味覚修飾技術,化学的苦味マスキング" , 都甲 潔、内田享弘(編), シーエムシー出版, 東京, 2007, pp. 160-170 (2007).
  10. 上釜兼人, 川島嘉明, 松田芳久(編) “最新製剤学”, 廣川書店,東京,(2007).
  11. 上釜兼人,
    レオロジー, 製剤を構成する物質・材料, “製剤学(改訂第5版)”, 四ツ柳智久, 壇上和美, 山本昌(編), 南江堂, 東京, 2007, pp. 63-70, pp. 91-96.

2006

  1. X.Y. Gao, K. Nishimura, F. Hirayama, H. Arima, K. Uekama, G. Schmid, K. Terao, D. Nakata, H. Fukumi,
    Enhanced Dissolution and Bioavailability of Coenzyme Q10 in Dogs Obtained by Inclusion Complexation with γ-Cyclodextrin,
    Asian J. Pharm. Sci., 1 (2), 95-102 (2006).
  2. K. Anzai, H. Kono, J.I. Mizoguchi, T. Yanagi, F. Hirayama, H. Arima, K. Uekama,
    Two-dimensional 13C-1H Heteronuclear Correlation NMR Spectroscopic Studies for the Inclusion Complex of Cyclomaltoheptaose (β-Cyclodextrin) with a New Helicobacter Pylori Eradicating Agent (TG44) in the Amorphous State,
    Carbohydr. Res., 341 (4), 499-506 (2006).
  3. Y. Sonoda, F. Hirayama, H. Arima, Y. Yamaguchi, W. Saenger, K. Uekama,
    Cyclodextrin-based Isolation of Ostwald’s Metastable Polymorphs Occurring during Crystallization,
    Chem. Commun., 2006 (5), 517-519 (2006). Selected as a hot article.
  4. Y. Hagiwara, H. Arima, Y. Miyamoto, F. Hirayama, K. Uekama,
    Preparation and Pharmaceutical Evaluation of Liposomes Entrapping Salicylic Acid/γ-Cyclodextrin Conjugate, Chem. Pharm. Bull., 54 (1), 26-32 (2006).
  5. T. Hara, F. Hirayama, H. Arima, Y. Yamaguchi, K. Uekama,
    Improvement of Solubility and Oral Bioavailability of 2-(N-Cyanoimino)-5-{(E)-4- styrylbenzylidene}-4-oxothiazolidine (FPFS-410) with Antidiabetic and Lipid-lowering Activities in Dogs by 2-Hydroxypropyl-β-cyclodextrin,
    Chem. Pharm. Bull., 54 (3), 344-349 (2006). Selected as a journal cover of issue 3.
  6. T. Hara, H. Arima, F. Hirayama, K. Uekama,
    Enhanced Bioavailability of a New Thiazolidine Derivative FPFS-410, an Antidiabetic and Lipid-lowering Drug, after Oral Administration of Its Hydroxypropyl-β-cyclodextrin Complex to Bile Duct-cannulated Rats,
    J. Pharm. Sci., 95, 1771-1782 (2006).
  7. Y. Sonoda, F. Hirayama, H. Arima, Y. Yamaguchi, W. Saenger, K. Uekama,
    Selective Crystallization of the Metastable Form IV Polymorph of Tolbutamide in the Presence of 2,6-Di-O-methyl-β-cyclodextrin in Aqueous Solution,
    Crystal Growth & Design, 6 (5), 1181-1185 (2006).
  8. K. Motoyama, H. Arima, H. Toyodome, T. Irie, F. Hirayama, K. Uekama,
    Effect of 2,6-Di-O-methyl-α-cyclodextrin on Hemolysis and Morphological Changes in Rabbit’s Red Blood Cells,
    Eur. J. Pharm. Sci.,29 , 111-119 (2006),
  9. H. Arima, Y. Chihara, M. Arizono, S. Yamashita, K. Wada, F. Hirayama, K. Uekama,
    Enhancement of Gene Transfer Activity Mediated by Mannosylated Dendrimer/α-Cyclodextrin Conjugate (Generation 3, G3),
    J. Control. Release, 116 (1), 64-74 (2006).
  10. H. Arima, Y. Hagiwara, F. Hirayama, K. Uekama,
    Enhancement of Antitumor Effect of Doxorubcin by Its Complexation with γ-Cyclodextrin in Pegylated Liposomes,
    J. Drug Targeting, 14 (4), 225-232 (2006).
  11. Y. Hagiwara, H. Arima, F. Hirayama, K. Uekama,
    Prolonged Retention of Doxorubicin in Tumor Cells by Encapsulation of γ-Cyclodextrin Complex in Pegylated Liposomes,
    J. Incl. Phenom. Macrocycl. Chem., 56 (1-2), 65-68 (2006).
  12. K. Motoyama, H. Arima, F. Hirayama, K. Uekama,
    Inhibitory Effects of 2,6-Di-O-methyl-3-O-acetyl-β-cyclodextrins with Various Degrees of Substitution of Acetyl Group on Macrophage Activation and Endotoxin Shock Induced by Lipopolysaccharide,
    J. Incl. Phenom. Macrocycl. Chem., 56 (1-2), 75-79 (2006).
  13. T. Tsutsumi, H. Arima, F. Hirayama, K. Uekama,
    Potential Use of Dendrimer/α-Cyclodextrin Conjugate as a Novel Carrier for Small Interfering RNA (siRNA),
    J. Incl. Phenom. Macrocycl. Chem. , 56 (1-2), 81-84 (2006).
  14. K. Nishimura, R. Hidaka, F. Hirayama, H. Arima, K. Uekama,
    Improvement of Dispersion and Release Properties of Nifedipine in Suppositories by Complexation with 2-Hydroxypropyl-β-cyclodextrin,
    J. Incl. Phenom. Macrocycl. Chem., 56 (1-2), 85-88 (2006).
  15. Y. Chihara, H. Arima, M. Arizono, K. Wada, F. Hirayama, K. Uekama,
    Serum-resistant Gene Transfer Activity of Mannosylated Dendrimer/α-Cyclodextrin Conjugate (G3),
    J. Incl. Phenom. Macrocycl. Chem., 56 (1-2), 89-93 (2006).
  16. T. Hara, F. Hirayama, H. Arima, Y. Yamaguchi, K. Uekama,
    Prominent Solubilizing Effect of 2-Hydoxypropyl-β-cyclodextrin on a New Thiazolidine Derivative (FPFS-410) with Antidiabetic and Lipid-lowering Activities through Inclusion Complex Formation,
    J. Incl. Phenom. Macrocycl. Chem., 56 (1-2), 135-139 (2006).
  17. T. Hara, H. Arima, F. Hirayama, K. Uekama,
    Enhanced Bioavailability of a New Thiazolidine Derivative FPFS-410, an Antidiabetic and Lipid-lowering Drug, after Oral Administration of Its Hydroxypropyl-β-cyclodextrin Complex to Bile Duct-cannulated Rats,
    J. Pharm. Sci., 95 (8), 1771-1782 (2006).
  18. S. Tavornvipas, F. Hirayama, S. Takeda, H. Arima, K. Uekama,
    Effects of Cyclodextrins on Chemically- and Thermally-induced Unfolding and Aggregation of Lysozyme and Basic Fibroblast Growth Factor,
    J. Pharm. Sci., 95 (12), 2722-2729 (2006).   
  19. K. Terao, D. Nakata, H. Fukumi, G. Schmid, H. Arima, F. Hirayama, K. Uekama,
    Enhancement of Oral Bioavailability of Coenzyme Q10 by the Complexation with γ-Cyclodextrin in Healthy Adult Volunteers,
    Nutr. Res., 26 (10), 503-508 (2006).
  20. K. Uekama, F. Hirayama, H. Arima,
    Recent Aspects of Cyclodextrin-based Drug Delivery System,
    J. Incl. Phenom. Macrocycl. Chem., 56 (1-2), 3-8 (2006).   
  21. K. Uekama, F. Hirayama, H. Arima,
    Pharmaceutical applications of cyclodextrins and their derivatives, "Cyclodextrins and their complexes", Ed. by H. Dodziuk, Wiley-VCH Verlag, Weinheim, 2006, pp. 381-422.
  22. 平山文俊,
    “第 9 章 ターゲティング”, “薬学教科書シリーズ第 7 巻 製剤化のサイエンス”, 東京化学同人, 東京, 2006, pp.169-177.

~2005

If you would like to see the publication list before 2005, Please go to the Home Page of Graduate School of Pharmaceutical Sciences, Kumamoto University.(http://seizai.pharm.kumamoto-u.ac.jp/index.html)

go to top